TY - JOUR
T1 - Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine
AU - Tsimberidou, Apostolia Maria
PY - 2017/5
Y1 - 2017/5
N2 - In the last decade, breakthroughs in technology have improved our understanding of genomic, transcriptional, proteomic, epigenetic aberrations and immune mechanisms in carcinogenesis. Genomics and model systems have enabled the validation of novel therapeutic strategies. Based on these developments, in 2007, we initiated the IMPACT (Initiative for Molecular Profiling and Advanced Cancer Therapy) study, the first personalized medicine program for patients with advanced cancer at The University of Texas MD Anderson Cancer Center. We demonstrated that in patients referred for Phase I clinical trials, the use of tumor molecular profiling and treatment with matched targeted therapy was associated with encouraging rates of response, progression-free survival and overall survival compared to non-matched therapy. We are currently conducting IMPACT2, a randomized study evaluating molecular profiling and targeted agents in patients with metastatic cancer. Optimization of innovative biomarker-driven clinical trials that include targeted therapy and/or immunotherapeutic approaches for carefully selected patients will accelerate the development of novel drugs and the implementation of precision medicine.
AB - In the last decade, breakthroughs in technology have improved our understanding of genomic, transcriptional, proteomic, epigenetic aberrations and immune mechanisms in carcinogenesis. Genomics and model systems have enabled the validation of novel therapeutic strategies. Based on these developments, in 2007, we initiated the IMPACT (Initiative for Molecular Profiling and Advanced Cancer Therapy) study, the first personalized medicine program for patients with advanced cancer at The University of Texas MD Anderson Cancer Center. We demonstrated that in patients referred for Phase I clinical trials, the use of tumor molecular profiling and treatment with matched targeted therapy was associated with encouraging rates of response, progression-free survival and overall survival compared to non-matched therapy. We are currently conducting IMPACT2, a randomized study evaluating molecular profiling and targeted agents in patients with metastatic cancer. Optimization of innovative biomarker-driven clinical trials that include targeted therapy and/or immunotherapeutic approaches for carefully selected patients will accelerate the development of novel drugs and the implementation of precision medicine.
KW - Clinical trials
KW - Genomic profiling
KW - Personalized medicine
KW - Phase I
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85017413288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017413288&partnerID=8YFLogxK
U2 - 10.1016/j.currproblcancer.2017.02.002
DO - 10.1016/j.currproblcancer.2017.02.002
M3 - Article
C2 - 28410846
AN - SCOPUS:85017413288
SN - 0147-0272
VL - 41
SP - 176
EP - 181
JO - Current Problems in Cancer
JF - Current Problems in Cancer
IS - 3
ER -